{{Rsnum
|rsid=1800909
|Gene=GGH
|Chromosome=8
|position=63038753
|Orientation=minus
|GMAF=0.2342
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=GGH
}}{{PharmGKB
|RSID=rs1800909
|Name_s=GGH: c.16T>C, p.Cys6Arg
|Gene_s=GGH
|Feature=Exon/NonSyn
|Evidence=PubMed ID:15284538
|Annotation=Patients (n= 66) with acute lymphoblastic leukemia showed large individual differences in cellular accumulation of long-chain MTXPG after high-dose methotrexate treatment. A SNP in the endoplasmic reticulum targeting sequence of human GGH, rs1800909 (16T>C), was detected in three acute lymphoblastic leukaemia patients with low GGH activity and four patients with high GGH activity.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165109544
}}

{{PharmGKB
|RSID=rs1800909
|Name_s=GGH: 16T>C
|Gene_s=GGH
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17286537
|Annotation=This study found that only patients with the GGH 16C-allele and one or no copies of the GGH 452C-16T haplotype were associated with good clinical improvement at 3 months upon treatment with methotrexate.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA165106758
}}
{{PMID Auto
|PMID=22018726
|Title=Genetic variation in folylpolyglutamate synthase and gamma-glutamyl hydrolase and plasma homocysteine levels in the Singapore Chinese Health Study
|OA=1
}}{{GET Evidence
|gene=GGH
|aa_change=Cys6Arg
|aa_change_short=C6R
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1800909
|overall_frequency_n=2416
|overall_frequency_d=10610
|overall_frequency=0.22771
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=2
|n_articles_annotated=2
|in_pharmgkb=Y
|nblosum100=8
|autoscore=1
|webscore=N
}}